Skip to main content
. 2020 Aug 18;11(33):3105–3117. doi: 10.18632/oncotarget.27684

Table 4. Historical controls for progression-free survival for each cohort.

Cohort Biliary Tract Cancer Bladder Cancer (CrCl: ≥ 60 mL/min and ECOG PS 0,1; fit) Bladder Cancer (CrCl: ≥ 30 to < 60 mL/min and/or ECOG PS 2; unfit) Squamous NCSLC
Historical median PFS duration 8.8 months 7.6 months 5.8 months 5 months

Abbreviations: CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PS, performance status.